Sanofi (SNY)
(Real Time Quote from BATS)
$56.31 USD
-0.01 (-0.02%)
Updated Aug 28, 2024 11:04 AM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Price, Consensus and EPS Surprise
SNY 56.31 -0.01(-0.02%)
Will SNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SNY
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kymera (KYMR) to Raise $225 Million Through Offering of Shares
How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?
The Zacks Analyst Blog Highlights Meta Platforms, Sanofi, CME and The Cato
Other News for SNY
UPDATE: UK PM Starmer in Berlin as hopes to "turn a corner on Brexit"
UK PM Starmer to hail "opportunity" to boost relationship with Europe
SAB Biotherapeutics initiated with bullish view at Oppenheimer, here's why
Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)
Regeneron announces latest Dupixent, itepekimab data at ERS